Fireside Panel Discussion on Diabetes sector
Arecor Therapeutics plc announced a virtual fireside panel discussion with Sequel Med Tech LLC on January 7, 2026, focusing on the future of diabetes treatment and innovation, but confirmed no new material information will be disclosed.
Select text to share a quote on X · sign in to keep highlights & notes in your AREC notes
Cambridge, UK, 6 January 2026: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company focused on drug development and delivery in diabetes and other cardiometabolic diseases, and Sequel Med Tech LLC ("Sequel"), a company developing state-of-the-art insulin delivery technologies, will be hosting a virtual fireside panel discussion on the future of the treatment journey for people with diabetes and factors driving diabetes innovation, on Wednesday 7 January 2026 at 16:00 GMT / 11:00 ET / 08:00 PT.
At this event, no new material information will be disclosed.
To register for the event, please email arecor@vigoconsulting.com or Investors@SequelMedTech.com.
About Sequel Med Tech
Headquartered in Manchester, New Hampshire, US, Sequel is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at diabetes management holistically to advance systems that make living with diabetes simpler and easier for all. Sequel was co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare leader Alan Lotvin, MD. Sequel's focus is to bring the latest developments in science and technology to the marketplace, helping drive more accessible drug delivery. For more information, please visit www.sequelmedtech.com.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.